Managing CML: What HCPs Need to Know
Dr. Michael Mauro discusses the evolving management of chronic myeloid leukemia (CML) with a focus on tyrosine kinase inhibitors (TKIs) and newly approved FDA therapies. The discussion covers initial therapy selection, managing side effects, TKI discontinuation criteria, and…